Diagnostic capabilities of I-131, Tl-201, and Tc-99m-MIBI scintigraphy for metastatic differentiated thyroid carcinoma after total thyroidectomy

Acta Medica Okayama

Volumn 59, Issue 3, 2005, Pages 99-107

  Fujie, Shunji ^a   Okumura, Yoshihiro ^a   Sato, Shuhei ^a   Akaki, Shiro ^a   Katsui, Kuniaki ^a   Himei, Kengo ^a   Takemoto, Mitsuhiro ^a   Kanazawa, Susumu ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

I 131 scintigraphy; Tc 99m MIBI scintigraphy; Thyroid cancer metastases; Tl 201 scintigraphy

Indexed keywords

IODINE 131; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; THALLIUM 201; THYROGLOBULIN;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CALCULATION; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; FEMALE; FOLLICULAR CARCINOMA; HUMAN; HUMAN TISSUE; MALE; MEDIASTINUM; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPILLARY CARCINOMA; RADIOLOGY; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROIDECTOMY; UTERINE CERVIX;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; CARCINOMA, PAPILLARY; CELL DIFFERENTIATION; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; POSTOPERATIVE CARE; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M SESTAMIBI; THALLIUM RADIOISOTOPES; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 21644474060     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Macapinlac HA: Head, neck, and thyroid; in Principles and Practice of Positron Emission Tomography, Wahl RL eds, Lippincott Williams and Wilkins, Philadelphia (2002) pp 157-165.
2. Macapinlac HA: Clinical usefulness of FDG PET in differentiated thyroid cancer. J Nucl Med (2001) 42: 77-78.
3. Kusakabe K, Inoue Y, Kawasaki Y, Maki M, Nara S, Kondo C, Nishioka T, Hiroe M, Shigeta A, Kurihara S, Demura H, Obara T, Fujimoto Y and Yamasaki T: Usefulness of Tl-201 chloride and NaI-131 scintigraphy in detection of metastasis from thyroid carcinoma. Kaku Igaku (1984) 21: 941-951 (in Japanese).
4. Grunwald F, Schomburg A, Bender H, Klemm E, Menzel C, Bultmann T, Palmedo H, Ruhlmann J, Kozak B and Biersack HJ: Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med (1996) 23: 312-319.
5. Grunwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, Schober O, Lerch H, Brandt-Mainz K, Burchert W, Hiltermann G, Cremerius U and Biersack HJ: Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med (1999) 26: 1547-1552.
6. Grunwald F, Menzel C, Fimmers R, Zamora PO and Biersack HJ: Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer. J Nucl Med (1996) 37: 1962-1964.
7. Blahd WH: Serum thyroglobulin in the management of thyroid cancer. J Nucl Med (1990) 31: 1771-1773.
8. de Geus-Oei LF, Oei HY, Hennemann G and Krenning EP: Sensitivity of I-123 whole -body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2002) 29: 768-774.
9. 201Tl-. Kaku Igaku (2000) 37: 89-98 (in Japanese).
10. Salvatore M, Carratu L and Porta E: Thallium-201 as a positive indicator for lung neoplasms: preliminary experiments. Radiology (1976) 121: 487-488.
11. Fukuchi M, Tachibana K, Kuwata K, Nishikawa A, Hyodo K, Okamoto E and Nagai K: Thallium-201 imaging in thyroid carcinoma-Appearance of a lymph-node metastasis. J Nucl Med (1978) 19: 195-196.
12. Hassan IM, Sahweil A, Constantinides C, Mahmoud A, Nair M, Omor YT and Abdel-Dayem HM: Uptake and kinetics of Tc-99m hexakis 2-methoxyisobutyl isonitrile in benign and malignant lesions in the lungs. Clin Nucl Med (1989) 14: 333-340.
13. Schlumberger M, Mancusi F, Baudin E and Pacini F: 131 I therapy for elevated thyroglobulin levels. Thyroid (1997) 7: 273-276.
14. Seabold JE, Gurll N, Schurrer ME, Aktay R and Kirchner PT: Comparison of 99mTc- methoxyisobutyl isonitrile and 201Tl scintigraphy for detection of residual thyroid cancer after 131 I ablative therapy. J Nucl Med (1999) 40: 1434-1440.
15. Dadparvar S, Chevres A, Tulchinsky M, Krishna-Badrinath L, Khan AS and Slizofski WJ: Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation. Eur J Nucl Med (1995) 22: 1330-1338.
16. Shiga T, Tsukamoto E, Nakada K, Morita K, Kato T, Mabuchi M, Yoshinaga K, Katoh C, Kuge Y and Tamaki N: Comparison of (18) F-FDG, (131) I-Na, and (201) Tl in diagnosis of recurrent or metastatic thyroid carcinoma. J Nucl Med (2001) 42: 414-419.
17. Ng DC, Sundram FX and Sin AE: 99m Tc-sestamibi and 131 I whole-body scintigraphy and initial serum thyroglobulin in the Management of differentiated thyroid carcinoma. J Nucl Med (2000) 41: 631 -635.
18. 131I accumulation and the therapeutic effect Rinsho hoshasen (Jpn J Clin Radiol) (2003) 48: 1087-1095 (in Japanese).
19. Ural S, Menda Y, Adalet I, Boztepe H, Ozbey N, Alagol F and Cantez S: Thallium-201, technetium-99m-tetrofosmin and iodine-131 in detecting differentiated thyroid carcinoma metastases. J Nucl Med (1998) 39: 1897-1902.
20. Hoefnagel CA, Delprat CC, Marcuse HR and de Vijlder JJ: Role of thallium-201 total-body scintigraphy in follow-up of thyroid carcinoma. J Nucl Med (1986) 27: 1854-1857.
21. Casara D, Rubello D, Saladini G, Masarotto G, Favero A, Girelli ME and Busnardo B: Different features of pulmonary metastases in differetiated thyroid cancer: natural history and multivariate stastical analysis of prognostic variables. J Nucl Med (1993) 34: 1626-1631.
22. Erdil TY, Onsel C, Kanmaz B, Caner B, Sonmezoglu K, Ciftci I, Turoglu T, Kabasakal L, Sayman HB and Uslu I: Comparison of 99mTc-methoxyisobutyl isonitrile and 201Tl scintigraphy in visualization of suppressed thyroid tissue. J Nucl Med (2000) 41: 1163-1167.
23. Carril JM, Quirce R, Serrano J, Banzo I, Jimenez-Bonilla JF, Tabuenca O and Barquin RG: Total-body scintigraphy with thallium-201 and iodine-131 in the follow-up of differentiated thyroid cancer. J Nucl Med (1997) 38: 686-692.
24. Miyamoto S, Kasagi K, Misaki T, Alam MS and Konishi J: Evaluation of technetium-99m-MIBI scintigraphy in metastatic differentiated thyroid carcinoma. J Nucl Med (1997) 38: 352-356.
25. Castillo LA, Yeh SD, Leepwer RD and Benua RS: Bone scans in bone metastases from functioning thyroid carcinoma. Clin Nucl Med (1980) 5: 200-209.
26. Nemec J, Nyvltova O, Blazek T, Vlcek P, Racek P, Novak Z, Preiningerova M, Hubackova M, Krizo M, Zimak J and Bilek R: Positive thyroid cancer scintigraphy using technetium-99m methoxyisobutylisonitrile. Eur J Nucl Med (1996) 23: 69-71.
27. Briele B, Hotze A, Kropp J, Bockisch A, Overbeck B, Grunwald F, Kaiser W and Biersack HJ: A comparison of 20ITl and 99mTc MIBI in the follow-up of differentiated thyroid carcinomas. Nuklearmedizin (1991) 30: 115-124.
28. ZaK IT, Seabold JE and Gurll NJ: Tc-99m MIBI scintigraphic detection of metastatic insular thyroid carcinoma. Clin Nucl Med (1995) 20: 31-36.
29. Learoyd DL, Roach PJ, Briggs GM, Delbridge LW, Wilmshurst EG and Robinson BG: Technetium-99m-sestamibi scanning in recurrent medullary thyroid carcinoma. J Nucl Med (1997) 38: 227-230.
30. Reynolds JC and Robbins J: The changing role of radioiodine in the management of differentiated thyroid cancer. Semin Nucl Med (1997) 27: 152-164.